伊立替康联合雷替曲塞三线治疗晚期胃癌的临床疗效观察

Irinotecan Compined with Raltitrexed in the Treatment of Advanced Gastric Cancer as Third-line Chemotherapy Regimen

目的观察伊立替康联合雷替曲塞三线治疗晚期胃癌的疗效及不良反应。方法 38例晚期胃癌患者予以伊立替康联合雷替曲塞方案治疗,至少治疗2周期。结果 37例患者可评价疗效,其中完全缓解1例、部分缓解10例、稳定11例、进展15例,有效率为29.7%(11/37),疾病控制率为59.5%(22/37)。中位疾病进展时间为5.6个月。常见不良反应为中性粒细胞减少、迟发性腹泻、恶心、呕吐等,多为Ⅰ、Ⅱ度。结论伊立替康联合雷替曲塞三线治疗晚期胃癌具有良好的疗效与耐受性,值得临床推广应用。

Objective To observe and evaluate the efficacy and adverse reactions of irinotecan compined with raltitrexed in the treatment of advanced gastric cancer as third-line chemotherapy regimen. Methods Thirty-eight patient with advanced gastric cancer received irinotecan combined with raltitrexed chemotherapy regimen for at least two cycles. Results Among the 38 patients,37 patients could be evaluated,included 1 patient with complete remission,10 patients with partial remission,11 patients with stable disease and 15 patients with progress disease,the overall response rate was 29. 7%（11/37）,the disease control rate was 59. 5%（ 22/37）. The median time to progress were 6. 3 months. The main adverse reactions were neutropenia,delayed diarrhea,nausea,vomiting,most of that were at Ⅰ and Ⅱ degree. Conclusion Irinotecan combined with raltitrexed as third-line regimen is effect and well-tolerated in the treatment of advanced gastric cancer.